Table 1.
CRFR manipulation affects OT content in BNSTdl microdialysates.
| Treatment (n per group) OT pg/100 μl MEAN ± SEM | Baseline 1 | Baseline 2 | Baseline 3 | 30 min | 60 min | 90 min | 120 min | 150 min |
|---|---|---|---|---|---|---|---|---|
| ACSF (n = 19) | 1.07 ± 0.05 | 1.03 ± 0.05 | 1.04 ± 0.06 | 1.04 ± 0.11 | 0.94 ± 0.04 | 0.93 ± 0.07 | 0.92 ± 0.06 | 0.87 ± 0.07 |
| As2B (n = 14) | 1.31 ± 0.16 | 1.13 ± 0.18 | 1.36 ± 0.25 | 1.79 ± 0.27 | 1.20 ± 0.16 | 1.44 ± 0.18 | 1.29 ± 0.21 | 1.29 ± 0.17 |
| CRF (n = 9) | 0.96 ± 0.17 | 1.08 ± 0.20 | 1.02 ± 0.14 | 1.12 ± 0.26 | 1.06 ± 0.19 | 1.30 ± 0.23 | 1.01 ± 0.20 | 1.07 ± 0.23 |
| Ucn3 (n = 7) | 1.32 ± 0.10 | 1.68 ± 0.20 | 1.30 ± 0.11 | 1.73 ± 0.16 | 1.52 ± 0.11 | 1.57 ± 0.09 | 1.25 ± 0.06 | 1.25 ± 0.10 |
| As2B+CRF (n = 7) | 1.26 ± 0.09 | 1.27 ± 0.13 | 1.23 ± 0.12 | 1.11 ± 0.09 | 1.07 ± 0.06 | 1.01 ± 0.08 | 1.03 ± 0.09 | 1.08 ± 0.11 |
| CRF+NBI 35965 (n = 8) | 0.88 ± 0.07 | 0.91 ± 0.10 | 1.04 ± 0.06 | 0.97 ± 0.12 | 1.06 ± 0.11 | 1.07 ± 0.08 | 0.98 ± 0.08 | 1.04 ± 0.12 |
| As2B+NBI 35965 (n = 6) | 0.81 ± 0.09 | 0.98 ± 0.07 | 1.02 ± 0.10 | 0.88 ± 0.08 | 0.93 ± 0.03 | 0.87 ± 0.07 | 0.92 ± 0.12 | 0.91 ± 0.12 |
OT content in BNSTdl microdialysates is expressed as MEAN ± SEM of OT (pg) in 100 μl microdialysis samples for each treatment group. Microdialysates were collected in 30 min intervals at baseline, and 30, 60, 90, 120, and 150 min after a drug delivery. Three baseline samples were collected in 30 min intervals before a drug delivery (ACSF, Artificial Cerebral Spinal Fluid; AS2B, Astressin 2B; CRF, Corticotropin-releasing factor; Ucn3, Urocortin 3; NBI 35965, CRFR1 antagonist). Underlined: Main treatment effect was observed in rats perfused with As2B, and post-hoc analysis showed significantly increased OT content in the first sample collected after drug infusion (30 min, P < 0.05) in comparison to pre-treatment OT content (Bonferroni's multiple comparisons).